<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / March 20, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.” data-reactid=”12″>NEW YORK, NY / ACCESSWIRE / March 20, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Geron Corporation (GERN)” data-reactid=”13″>Geron Corporation (GERN)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Investors Affected : March 19, 2018 – September 26, 2018” data-reactid=”14″>Investors Affected : March 19, 2018 – September 26, 2018
A class action has commenced on behalf of certain shareholders in Geron Corporation. The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shareholders may find more information at https://securitiesclasslaw.com/securities/geron-corporation-et-al-loss-submission-form/?id=5761&from=1” data-reactid=”16″>Shareholders may find more information at https://securitiesclasslaw.com/securities/geron-corporation-et-al-loss-submission-form/?id=5761&from=1
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Align Technology, Inc. (ALGN)” data-reactid=”17″>Align Technology, Inc. (ALGN)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Investors Affected : April 24, 2019 – July 24, 2019” data-reactid=”18″>Investors Affected : April 24, 2019 – July 24, 2019
A class action has commenced on behalf of certain shareholders in Align Technology, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Align was then experiencing a significant decline in demand for its products in the important Chinese market; (b) Chinese consumer sentiment towards the Company was deteriorating; and (c) as a result of the foregoing, Defendants’ positive statements about Align and its businesses were lacking in a reasonable basis.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shareholders may find more information at https://securitiesclasslaw.com/securities/align-technology-inc-loss-submission-form/?id=5761&from=1” data-reactid=”20″>Shareholders may find more information at https://securitiesclasslaw.com/securities/align-technology-inc-loss-submission-form/?id=5761&from=1
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Cronos Group Inc. (CRON)” data-reactid=”21″>Cronos Group Inc. (CRON)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Investors Affected : May 9, 2019 – March 2, 2020” data-reactid=”22″>Investors Affected : May 9, 2019 – March 2, 2020
A class action has commenced on behalf of certain shareholders in Cronos Group Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company’s ability to timely file its periodic reports; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shareholders may find more information at https://securitiesclasslaw.com/securities/cronos-group-inc-loss-submission-form/?id=5761&from=1” data-reactid=”24″>Shareholders may find more information at https://securitiesclasslaw.com/securities/cronos-group-inc-loss-submission-form/?id=5761&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:” data-reactid=”26″>CONTACT:
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770″ data-reactid=”27″>The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: The Gross Law Firm” data-reactid=”28″>SOURCE: The Gross Law Firm
View source version on accesswire.com:
https://www.accesswire.com/581817/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-GERN-ALGN-and-CRON
Add Comment